FORT WASHINGTON, Pa., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced that it has commenced a proposed follow-on public offering of 3,000,000 shares of its common stock. All shares of common stock to be sold in the offering will be offered by Vitae. Vitae also expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock in the public offering.
Stifel, BMO Capital Markets and Piper Jaffray & Co. are acting as joint book-running managers and JMP Securities and Wedbush PacGrow Life Sciences are acting as co-managers for the offering.
A registration statement relating to the shares to be sold in the offering has been filed with the Securities and Exchange Commission, but has not yet become effective. The shares may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. The offering is being made only by means of a prospectus. Copies of the prospectus related to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, telephone: (415) 364-2720, email: email@example.com; or from BMO Capital Markets Corp., 3 Times Square, 26th Floor, New York, NY 10036, Attention: Equity Syndicate Department, telephone: (800) 414-3627, email: firstname.lastname@example.org; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, telephone: (800) 747-3924, email: email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
Vitae Pharmaceuticals, Inc.
Richard S. Morris, CPA
Chief Financial Officer
6 Degrees PR